



Xgene Pharmaceutical Inc. Announces Dosing of First Patient in a Phase 2b/3 Trial of XG005 for the Treatment of Pain Following Bunionectomy Surgery.

AUG 24, 2023 (time and zone, source i.e. PRNewswire)

Taipei, Taiwan (or other office location) Aug. 25, 2023. Xgene Pharmaceutical, a clinical-stage pharmaceutical company focusing on pain and other central nervous system (CNS) conditions, today announced the dosing of the first patient in the Phase 2b/3 study in the United States - a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of XG005 oral tablet in subjects undergoing bunionectomy.

The XG005 trial, conducted in the US with Lotus Clinical Research LLC, has a planned enrollment of approximately 450 patients undergoing bunionectomy in a randomized, double-blind, placebo-controlled, 3-day treatment, evaluating the pharmacokinetic profile, safety, and analgesic efficacy of two doses of XG005 compared to placebo. In addition, the company will assess the reduction in post-surgical consumption of opioid analgesics.

"The dosing of the first patient in this important study represents a significant milestone in the ongoing late-stage development program of XG005 oral tablet for treatment of acute and chronic pain," said Dr. Leon Jiang, Chief Medical and Senior Vice President of Xgene Pharmaceutical. "The clinical development of XG005 includes a Phase 2 trial in chronic pain of the osteoarthritis of the knee which is ongoing in China and a trial in cancer pain which is currently in a planning stage," said Dr. Jiang.

XG005 is a non-opioid new chemical entity (NCE) with novel dual-mechanism of action targeting an anti-inflammatory and neuropathic components of pain. When released into the blood stream, by inhibiting the pain signals due to inflammation and nerve injury simultaneously, XG005 can further enhance the analgesic effect and improve the safety profile while reducing the use and side effects of opioids in a post-operative setting.

About XG005

XG005, a new chemical entity (NCE) and a novel non-opioid dual-action prodrug conjugate of an NSAID and a calcium channel inhibitor, is simultaneously targeting an anti-inflammatory and neuropathic pathways of pain. Through its unique multi-modal analgesic mechanism, XG005 can inhibit pain signals more effectively and achieve better clinical efficacy in a wide range of painful conditions.

About Xgene Pharmaceutical, Inc.

Xgene Pharmaceutical Inc. is a clinical stage, venture capital-backed, international company utilizing their proprietary linker technology to create novel, multimodal, conjugated molecules for treatment of pain and other neurological disorders. Xgene's proprietary linker technology, tailored to the recognized profiles of specific existing and newly discovered drugs, overcomes the challenges of the multimodal drug combination approach and offers potentially better, safer, and more efficient treatments. Current programs are focused on improving the efficacy and tolerability of pain therapeutics with a pipeline comprising late-stage clinical programs as well as assets in discovery and preclinical development. Since its establishment, Xgene has been recognized and supported by Morningside Capital, TF Capital, Ping'an Venture Capital, Hengxu Capital, CITIC Securities and other investment institutions.

Learn more at www.xgenepharm.com